GlassScriptPhysician profile
Daniel N Coar
NPI 1750389730
$721.26
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $61.70 · 2021: $319 · 2022: $19.91.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $323.88 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $86.67 | 2019-2020 | |
| Amgen INC. | $68.52 | 2019-2022 | |
| Akebia Therapeutics INC | $63.17 | 2019 | |
| Horizon Therapeutics Plc | $61.05 | 2019 | |
| Fresenius USA Marketing, INC. | $46.89 | 2019-2020 | |
| Angiodynamics, INC. | $23.13 | 2020 | |
| Amicus Therapeutics, INC. | $22.14 | 2019 | |
| Shire North American Group INC | $13.75 | 2019 | |
| Chiesi USA, INC. | $12.06 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Coar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.